» Articles » PMID: 26361355

High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model

Overview
Journal PLoS One
Date 2015 Sep 12
PMID 26361355
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is a prevalent neurodegenerative disorder with pathological features including death of dopaminergic neurons in the substantia nigra and intraneuronal accumulations of Lewy bodies. As the main component of Lewy bodies, α-synuclein is implicated in PD pathogenesis by aggregation into insoluble filaments. However, the detailed mechanisms underlying α-synuclein induced neurotoxicity in PD are still elusive. MicroRNAs are ~20nt small RNA molecules that fine-tune gene expression at posttranscriptional level. A plethora of miRNAs have been found to be dysregulated in the brain and blood cells of PD patients. Nevertheless, the detailed mechanisms and their in vivo functions in PD still need further investigation. By using Drosophila PD model expressing α-synuclein A30P, we examined brain miRNA expression with high-throughput small RNA sequencing technology. We found that five miRNAs (dme-miR-133-3p, dme-miR-137-3p, dme-miR-13b-3p, dme-miR-932-5p, dme-miR-1008-5p) were upregulated in PD flies. Among them, miR-13b, miR-133, miR-137 are brain enriched and highly conserved from Drosophila to humans. KEGG pathway analysis using DIANA miR-Path demonstrated that neuroactive-ligand receptor interaction pathway was most likely affected by these miRNAs. Interestingly, miR-137 was predicted to regulate most of the identified targets in this pathway, including dopamine receptor (DopR, D2R), γ-aminobutyric acid (GABA) receptor (GABA-B-R1, GABA-B-R3) and N-methyl-D-aspartate (NMDA) receptor (Nmdar2). The validation experiments showed that the expression of miR-137 and its targets was negatively correlated in PD flies. Further experiments using luciferase reporter assay confirmed that miR-137 could act on specific sites in 3' UTR region of D2R, Nmdar2 and GABA-B-R3, which downregulated significantly in PD flies. Collectively, our findings indicate that α-synuclein could induce the dysregulation of miRNAs, which target neuroactive ligand-receptor interaction pathway in vivo. We believe it will help us further understand the contribution of miRNAs to α-synuclein neurotoxicity and provide new insights into the pathogenesis driving PD.

Citing Articles

Degenerative Disease Diagnosis and Analysis Based on Tissue Specificity of DNA Methylation.

Zhao J, Yao W, Gao H, Kuang Z, Shi L, Wang H Int J Mol Sci. 2025; 26(2).

PMID: 39859168 PMC: 11765164. DOI: 10.3390/ijms26020452.


Parkinson Disease -Targeted Nanocapsules for Synergistic Treatment: Combining Dopamine Replacement and Neuroinflammation Mitigation.

Liu Z, Xiang S, Chen B, Li J, Zhu D, Xu H Adv Sci (Weinh). 2024; 11(46):e2404717.

PMID: 39431293 PMC: 11633476. DOI: 10.1002/advs.202404717.


MicroRNAs regulation in Parkinson's disease, and their potential role as diagnostic and therapeutic targets.

Shaheen N, Shaheen A, Osama M, Nashwan A, Bharmauria V, Flouty O NPJ Parkinsons Dis. 2024; 10(1):186.

PMID: 39369002 PMC: 11455891. DOI: 10.1038/s41531-024-00791-2.


The Role of miR-137 in Neurodegenerative Disorders.

Bodai L, Borosta R, Ferencz A, Kovacs M, Zsindely N Int J Mol Sci. 2024; 25(13).

PMID: 39000336 PMC: 11241563. DOI: 10.3390/ijms25137229.


A targeted CRISPR-Cas9 mediated F0 screen identifies genes involved in establishment of the enteric nervous system.

Moreno-Campos R, Singleton E, Uribe R PLoS One. 2024; 19(5):e0303914.

PMID: 38809858 PMC: 11135701. DOI: 10.1371/journal.pone.0303914.


References
1.
Price D, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D . Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One. 2010; 5(11):e14020. PMC: 2982819. DOI: 10.1371/journal.pone.0014020. View

2.
Van der Perren A, Macchi F, Toelen J, Carlon M, Maris M, de Loor H . FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease. Neurobiol Aging. 2015; 36(3):1559-68. DOI: 10.1016/j.neurobiolaging.2015.01.014. View

3.
Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A . TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A. 2013; 110(19):E1817-26. PMC: 3651458. DOI: 10.1073/pnas.1305623110. View

4.
Cardo L, Coto E, de Mena L, Ribacoba R, Moris G, Menendez M . Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J Neurol. 2013; 260(5):1420-2. DOI: 10.1007/s00415-013-6900-8. View

5.
Devine M . Proteasomal inhibition as a treatment strategy for Parkinson's disease: the impact of α-synuclein on Nurr1. J Neurosci. 2012; 32(46):16071-3. PMC: 6794012. DOI: 10.1523/JNEUROSCI.4224-12.2012. View